WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Dan R. Koeppen
Partner
Corporate
San Diego
dkoeppen@wsgr.com

D858-350-2393

Download vCard
LinkedIn
Open PDF
  • Life Science and Tech Expertise

    Dan has extensive experience working with biotech, consumer products, data security, medical device, pharmaceutical, semiconductor, software, and social media companies through all stages of their growth.

  • Underwriter Representation

    Dan regularly represents leading investment banks in their underwriting transactions and advises numerous venture capital firms and corporate strategic investors in connection with their investments in emerging growth companies.

Dan Koeppen is a corporate and securities partner in the firm's San Diego office. Dan specializes in corporate governance, mergers and acquisitions, public offerings, and venture capital financings. He has extensive experience representing public and private life science and technology companies in a wide range of sectors, including biotechnology, consumer products, data security, medical device, pharmaceutical, semiconductor, software, and social media, through all stages of their growth from start-up to mature public companies. In addition, Dan represents leading investment banks in their underwriting transactions, and regularly advises numerous venture capital firms and corporate strategic investors in connection with their investments in emerging growth companies.

Experience

Dan Koeppen is a corporate and securities partner in the firm's San Diego office. Dan specializes in corporate governance, mergers and acquisitions, public offerings, and venture capital financings. He has extensive experience representing public and private life science and technology companies in a wide range of sectors, including biotechnology, consumer products, data security, medical device, pharmaceutical, semiconductor, software, and social media, through all stages of their growth from start-up to mature public companies. In addition, Dan represents leading investment banks in their underwriting transactions, and regularly advises numerous venture capital firms and corporate strategic investors in connection with their investments in emerging growth companies.

Education
  • J.D., UCLA School of Law, 2004
  • B.B.A., Accounting and Information Systems, University of Wisconsin, Madison, 2001
Honors
  • Named among SDBJ’s Leaders of Influence in Life Sciences, 2024
  • Selected for inclusion in Lawdragon's 2025 and 2026 500 Leading Dealmakers in America guides
  • Named a finalist for “Venture Capital Attorney of the Year” for the LMG Life Sciences 2023 Americas Awards

  • Recognized as a "Life Science Star" in the intellectual property section of LMG Life Sciences in 2022
Admissions
  • State Bar of California
  • U.S. District Court for the Central District of California
Credentials
Education
  • J.D., UCLA School of Law, 2004
  • B.B.A., Accounting and Information Systems, University of Wisconsin, Madison, 2001
Honors
  • Named among SDBJ’s Leaders of Influence in Life Sciences, 2024
  • Selected for inclusion in Lawdragon's 2025 and 2026 500 Leading Dealmakers in America guides
  • Named a finalist for “Venture Capital Attorney of the Year” for the LMG Life Sciences 2023 Americas Awards

  • Recognized as a "Life Science Star" in the intellectual property section of LMG Life Sciences in 2022
Admissions
  • State Bar of California
  • U.S. District Court for the Central District of California
Focus Areas
  • Biotech
  • Capital Markets
  • Corporate
  • Corporate Governance
  • Corporate Life Sciences
  • Emerging Companies and Venture Capital
  • Life Sciences
  • Mergers & Acquisitions
Recent Insights
Client Highlights
Wilson Sonsini Advises Whitehawk Therapeutics on $87.5 Million PIPE Financing
On May 13, 2026, Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate cancer treatments, announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $87.5 million, before deducting placement agent fees and other private placement expenses. The PIPE financing includes participation from existing investors including Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1 Capital Management, Acuta Capital Partners, StemPoint Capital LP, Invus, as well as members of the company’s executive team. Wilson Sonsini Goodrich & Rosati advised Whitehawk on the transaction.
Learn More
Client Highlights
Wilson Sonsini Represents Investors in Windward Bio’s $165 Million Crossover Financing
On May 4, 2026, Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. Wilson Sonsini Goodrich & Rosati represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in the transaction.

Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.

The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Learn More
View All
Recent Events
Affiliated Programs
West Coast NextGen VC Forum
LaunchBio’s NextGen VC Forum is the premier event for venture capital professionals to deepen their knowledge of the life science and biotech sectors while building meaningful connections across the industry. The forum features expert led sessions that offer practical insights into evaluating, supporting, and scaling science-backed startups. Networking is built into the program to help participants expand their reach and grow their networks. Co-created with LaunchBio, the half-day forum includes a networking lunch, three interactive one-hour sessions, and a closing happy hour.
Learn More
Affiliated Programs
NextGen VC Forum - NYC 2024
LaunchBio’s NextGen VC Forum is the premiere event for mid-level venture capital associates to expand their skills and expertise while growing their network. Attendees benefit from curated education sessions from industry leaders to supplement existing expertise. Networking is essential in sourcing deals and one of the primary roles for associates, we’ve built it into the program for participants to be able to walk away with new life science and biotech contacts. The half-day forum created with Wilson Sonsini includes a networking lunch, three one-hour sessions, and a happy hour.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.